Terug naar bedrijfspagina

Nieuws over Ucb

04/12/2025 UCB - deelt toonaangevend wetenschappelijk onderzoek en ontwikkelingen op de jaarlijkse bijeenkomst van de American Epilepsy Society (04.12.2025)

06/11/2025 Tubize - Private placement of Financière de Tubize shares (06.11.2025)

04/11/2025 UCB - Amerikaanse FDA keurt KYGEVVI® (doxecitine en doxribtimine) goed, de eerste en enige behandeling voor volwassenen en kinderen met thymidinekinase 2-deficiëntie (TK2d) (04.11.2025)

31/10/2025 UCB - BIMZELX® (bimekizumab-bkzx) data in hidradenitis suppurativa showed improvements in pain and resolution of draining tunnels sustained to three years (31.10.2025)

29/10/2025 UCB - onthult nieuwe gegevens voor RYSTIGGO ®▼ en ZILBRYSQ ®▼ voor gMG tijdens de jaarlijkse AANEM-bijeenkomst van 2025 en de wetenschappelijke sessie van MGFA (29.10.2025)

26/10/2025 UCB - Media Room: BIMZELX® (bimekizumab-bkzx) three year rheumatology data at ACR 2025 (UCB Media Room: BIMZELX® (bimekizumab-bkzx) driejarige reumatologiegegevens op ACR 2025 (26.10.2025)

14/10/2025 UCB - Media Room: Final analysis of open-label extension (OLE) study of Fintepla®▼ (fenfluramine) in Lennox-Gastaut syndrome published in Epilepsy and Behavior (14.10.2025)

13/10/2025 UCB - Results published in Neurology highlight a 95% reduction in risk of death with pyrimidine nucleos(t)ide therapy in patients with thymidine kinase 2 deficiency (TK2d)(13.10.2025)

24/09/2025 Financière de Tubize - versterkt haar expertise in de biopharmasector door de benoeming van 2 nieuwe bestuurders (24.09.2025)

18/09/2025 UCB - kondigt succesvolle eerste proef met galvokimig bij patiënten met matige tot ernstige atopische dermatitis aan bij EADV (18.09.2025)

17/09/2025 UCB -Gegevens over BIMZELX[®] ▼ bij matige plaque psoriasis bij EADV lieten een remissie van 4 jaar zien, en het potentieel om het pogressie van psoriatische artritis te verminderen (17.09.2025)

29/08/2025 UCB - presenteert nieuwste onderzoek en klinische vooruitgang binnen toonaangevende epilepsieportfolio op International Epilepsy Congress (29.08.2025)

02/08/2025 Financiere de Tubize - Halfjaarlijks verslag 2025 Gereglementeerde informatie 2 augustus 2025 (02.08.2025)

02/08/2025 Tubize -Halfjaarlijks verslag 2025 Gereglementeerde informatie 2 augustus 2025 (02.08.2025)

31/07/2025 UCB - Media Room: Half Year Results 2025 (UCB Media Room: Halfjaarresultaten 2025) (31.07.2025)

08/07/2025 UCB - presents latest research advancements at European Pediatric Neurology Society Congress (08.07.2025)

27/06/2025 UCB - Media Room: Positive results from GEMZ phase 3 study of fenfluramine in CDKL5 Deficiency Disorder (27.06.2025)

27/06/2025 UCB - announces positive results from GEMZ phase 3 study of fenfluramine in CDKL5 Deficiency Disorder (27.06.2025)

21/06/2025 UCB - presenteert nieuwe gegevens uit haar neurologieportfolio op het 11e congres van de European Academy of Neurology (EAN) 2025 (21.06.2025)

13/06/2025 UCB - kondigt grote Amerikaanse investering aan om de productiecapaciteit voor biologische producten uit te breiden (13.06.2025)

12/06/2025 UCB - Media Room: Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology ( 12.06.2025)

11/06/2025 UCB - BIMZELX®▼(bimekizumab) three-year data at EULAR 2025 showed lasting efficacy and control of inflammation in psoriatic arthritis and axial spondyloarthritis (11.06.2025)

20/05/2025 UCB - Domino Data Lab Collaborate to Modernize Statistical Computing Environment in Life Sciences (20.05.2025)

13/05/2025 UCB - presenteert uitgebreide dataset op de 15e internationale conferentie van de Myasthenia Gravis Foundation of America (MGFA)(13.05.2025)

09/05/2025 UCB - RYSTIGGO (rozanolixizumab) krijgt goedkeuring in Japan voor twee nieuwe toedieningsmethoden, terwijl UCB het ONWARD-programma voor patiëntenondersteuning start (09.05.2025)

25/04/2025 UCB - Algemene aandeelhoudersvergadering van UCB 2025 (25.04.2025)

12/04/2025 UCB - Wereldwijde gegevens tonen de effectiviteit van romosozumab in de praktijk aan voor patiënten met een hoog fractuurrisico (12.04.2025)

03/04/2025 UCB - presenteert het nieuwste onderzoek in het toonaangevende neurologieportfolio op de bijeenkomst van de American Academy of Neurology (AAN) in 2025 (03.04.2025)

01/04/2025 UCB - presents key data from Alzheimer’s and Parkinson’s disease research programs at AD/PD 2025 (01.04.2025)

22/03/2025 Tubize - jaarverslag 2024 (22.03.2025)

19/03/2025 UCB - Nieuwe gegevens over experimentele therapie voor thymidinekinase 2-deficiëntie gepresenteerd op de Muscular Dystrophy Association (MDA) 2025-conferentie (19.03.2025)

08/03/2025 UCB - Media Room: Share Repurchase Program 2025 to cover UCB's Long Term Incentive Plans for employees (10.03.2025)

07/03/2025 UCB - BIMZELX (07.03.2025)

27/02/2025 UCB - Media Room: 2024 Full Year Results (UCB Media Room: Resultaten voor het volledige jaar 2024) (27.02.2025)

12/02/2025 UCB - Media Room: BIMZELX bimekizumab) two-year data in HS at EHSF 2025 (UCB Media Room: BIMZELX (bimekizumab) tweejarige gegevens in HS op EHSF 2025) (12.02.2025 )

10/02/2025 UCB - Media Room: UCB Advances Long-Term Innovation Strategy with New Research & Development Facility at Braine-l’Alleud Campus (10.02.2025)

31/01/2025 UCB -RYSTIGGO(rozanolixizumab), for generalized myasthenia gravis (gMG), receives EU approval for two new administration methods (31.01.2025)

15/01/2025 UCB - showcases decade of growth and Patient Value Strategy driving differentiated innovation (15.01.2025)

09/01/2025 UCB - Media Room: partnership with Ailux Biologics, a Division of XtalPi, on Biologics AI Platform (09.01.2025)

16/12/2024 UCB - Media Room: Findings from minzasolmin proof-of-concept ORCHESTRA study shape next steps in UCB Parkinson’s research program (16.12.2024)

29/11/2024 UCB - Focuses on New Launch and Completes Divestment of Mature Product Business in China (29.11.2024)

27/11/2024 UCB - Media Room: latest scientific research in epilepsy presented at American Epilepsy Society (AES) Annual Meeting (27.11.2024)

20/11/2024 UCB - receives U.S. FDA approval for BIMZELX® (bimekizumab-bkzx) as the first IL-17A and IL-17F inhibitor for adults with moderate to severe hidradenitis suppurativa (20.11.2024)

19/11/2024 UCB - Media Room: Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology (19.11.2024)

15/11/2024 UCB - New BIMZELX® (bimekizumab-bkzx) data at ACR Convergence 2024 highlights UCB’s efforts to deliver differentiated care for patients with psoriatic arthritis and axial spondyloarthritis (14.11.2024)

05/11/2024 UCB - Media Room: UCB completes sale of established brands and updates 2024 financial guidance (05.11.2024)

31/10/2024 UCB - Presents Encouraging Data on Bepranemab in Early Alzheimer’s Disease in Phase 2a Study at CTAD 2024 (31.10.2024)

22/10/2024 UCB - Announces Bepranemab Phase 2a Study Results Accepted for Late-Breaking Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting (22.10.2024)

14/10/2024 UCB - receives U.S. FDA approval for 320 mg single-injection device presentations of BIMZELX (bimekizumab-bkzx) (14.10.2024)

11/10/2024 UCB - showcases new data for gMG management at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting (11.10.2024)

04/10/2024 UCB - Media Room: Transparency notification BlackRock, Inc. (04.10.2024)

02/10/2024 UCB - Transparantieverklaring BlackRock, Inc. (02.10.2024)

01/10/2024 UCB - Transparantieverklaring BlackRock, Inc. (0110.24)

30/09/2024 UCB - announces a head-to-head study evaluating BIMZEL(bimekizumab) versus SKYRIZI (risankizumab) in active psoriatic arthritis (30.09.2024)

27/09/2024 UCB - Media Room: late-breaking two-year data for BIMZEL(bimekizumab) in moderate to severe hidradenitis suppurativa at EADV 2024 (27.09.2024)

27/09/2024 UCB - Transparantieverklaring BlackRock, Inc. (27.09.2024)

26/09/2024 UCB - Media Room: Transparency notification BlackRock, Inc. (26.09.2024)

25/09/2024 UCB - Media Room: Transparency notification BlackRock, Inc. (25.09.2024)

25/09/2024 UCB - Media Room: New 4-year data for BIMZELX (bimekizumab) in moderate to severe plaque psoriasis at EADV 2024 (25.09.2024)

24/09/2024 UCB - Media Room: Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in SLE (24.09.2024)

23/09/2024 UCB - announces U.S. FDA approvals for BIMZELX (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis (23.09.2024)

09/09/2024 UCB - New insights highlight unmet needs for people living with Lennox-Gastaut syndrome and significant burden of the disease (09.09.2024)

07/09/2024 UCB - Transparantieverklaring BlackRock, Inc.(07.09.2024)

06/09/2024 UCB - Media Room: Transparency notification BlackRock, Inc.(06.09.2024)

06/09/2024 UCB - Media Room: new data across expansive epilepsies portfolio at 15th European Epilepsy Congress (EEC) (06.09.2024)

05/09/2024 UCB - Transparantieverklaring BlackRock, Inc.(05.09.2024)

03/09/2024 UCB - Transparantieverklaring BlackRock, Inc. (03.09.2024)

29/08/2024 UCB - Media Room: Transparency notification BlackRock, Inc. (29.08.2024)

26/08/2024 UCB - Media Room: UCB to Accelerate Innovation and Strategic Partnerships, Divesting Mature Product Portfolio in China

24/08/2024 UCB - Transparantieverklaring BlackRock, Inc. (24.08.2024)

22/08/2024 UCB- Transparantieverklaring BlackRock, Inc. (22.08.2024)

10/08/2024 UCB - Media Room: Transparency notification (10.08.2024)

09/08/2024 UCB - Transparantieverklaring Goldman Sachs (09.08.2024)

08/08/2024 UCB - Transparency notification Goldman Sachs (08.08.2024)

05/08/2024 UCB announces European Commission approval for 320 mg device presentations of BIMZELX(bimekizumab) - 05.08.2024

25/07/2024 UCB - Sterke start van UCB’s decennium van groei (25.07.2024)

28/06/2024 UCB - spotlights new analyses and patient insights supporting its recently launched gMG portfolio at the 10th Congress of the European Academy of Neurology (EAN) (28.06.2024)

26/06/2024 UCB - epilepsy drug BRIVIACT(brivaracetam)1 approved in Japan for treatment of focal onset seizures (26.06.2024)

13/06/2024 UCB -New data support the value of CIMZIA for women living with chronic rheumatic diseases throughout pregnancy and postpartum, and for people living with RA and high rheumatoid factor levels (13.06.2024)

12/06/2024 UCB - to share first presentations of BIMZELX(bimekizumab) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024 (12.06.2024)

10/06/2024 UCB - Global experts release new guidelines on prevention of progression of epileptic seizures, addressing critical treatment gaps (10.06.2024)

31/05/2024 UCB - announces positive CHMP opinion for two 320 mg device presentations of BIMZELX (bimekizumab) (31.05.2024)

23/05/2024 UCB - announces publication in The Lancet of phase 3 bimekizumab▼ trials in moderate to severe hidradenitis suppurativa (23.05.2024)

18/05/2024 UCB - Media Room: Transparency notification Wellington (18.05.2024)

08/05/2024 UCB - Media Room: UCB presents final open-label extension F®▼(fenfluramine) data at International Child Neurology Congress (ICNC) Annual Meeting (08.05.2024)

25/04/2024 UCB - off to a Good Start into 2024 – Progressing on its Growth Path for a Decade Plus (25.04.2024)

25/04/2024 UCB - off to a Good Start into 2024 – Progressing on its Growth Path for a Decade Plus (25.04.2024)

25/04/2024 UCB - Media Room UCB’s General Meeting of Shareholders 2024 (25.04.2024

24/04/2024 UCB - Transparantieverklaring FMR LLC (24.04.2024)

22/04/2024 UCB - receives European Commission approval for BIMZELX▼(bimekizumab) as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa (22.04.2024)

17/04/2024 UCB - FINTEPLA (fenfluramine) oral solution approved in Japan for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) (17.04.2014)

12/04/2024 UCB - Media Room: UCB presents new data highlighting developments across expansive neurology portfolio at 76th AAN Annual Meeting (12.04.2024)

12/04/2024 UCB - Media Room: Latest real-world evidence presented at WCO-IOF-ESCEO assesses how EVENITY(romosozumab) can help to close the treatment gap in osteoporosi (12.04.2024)

04/04/2024 UCB - FDA Accepts Supplemental Biologics License Applications for BIMZELX (bimekizumab-bkzx) for Moderate to Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations (04.04.2024)

22/03/2024 UCB - receives positive CHMP opinion for BIMZELX®▼(bimekizumab) for the treatment of adults with moderate to severe hidradenitis suppurativa (22.03.2024)

08/03/2024 UCB - Bimekizumab 48-week Phase 3 analyses in moderate to severe hidradenitis suppurativa showed sustained improvements in skin pain and draining tunnel count (08.03.2024)

04/03/2024 UCB announces strategic investment in IMIDomics, Inc to advance breakthrough solutions for immune-mediated inflammatory diseases (04.03.2024)

28/02/2024 UCB - FY Results 2023 (28.02.2024)

09/02/2024 UCB - Latest analyses of bimekizumab phase 3 studies in moderate to severe hidradenitis suppurativa to be presented at EHSF 2024 (09.02.2024)

08/01/2024 UCB- announces European Commission approval of RYSTIGGO (rozanolixizumab) for the treatment of adults with generalized myasthenia gravis in Europe (08.01.2024)

27/12/2023 UCB - BIMZELX (bimekizumab) Receives Approval in Japan for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis (27/12/2023)

04/12/2023 UCB - announces European Commission approval of ZILBRYSQ (zilucoplan) for the treatment of adults with generalized Myasthenia Gravis (04.12.2023)

01/12/2023 UCB - presents new data advancing patientfocused scientific leadership at American Epilepsy Society Annual Meeting (01.12.2023)

16/11/2023 UCB - ‘Rheumacensus’ experts unite and call for essential psoriatic arthritis and axial spondyloarthritis care improvements (16.11.2023)

13/11/2023 UCB - Post hoc analysis showed meaningful efficacy of certolizumab pegol for RA patients with high Rheumatoid Factor (RF) levels (13.11.2023)

10/11/2023 UCB - CHMP positive opinion for rozanolixizumab for treatment of adults with generalized myasthenia gravis in Europe (10.11.2023)

09/11/2023 UCB - rondt de aanbieding aan het publiek van vastrentende obligaties met succes af en beslist om de inschrijvingsperiode vroegtijdig te beëindigen (09.11.2023)